Optimer Pharmaceuticals to Present at September 2011 Investor Conferences

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences:

- R.W. Baird Health Care Conference on Wednesday, September 7, 2011 at 12:45 p.m. Eastern Time at the New York Palace in New York.
- Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 13, 2011 at 8:00 a.m. Eastern Time at the Grand Hyatt in New York.
- UBS Global Life Sciences Conference on Monday, September 19, 2011 at 12:00 p.m. Eastern Time at the Grand Hyatt in New York.
- JMP Securities Healthcare Conference on Tuesday, September 27, 2011 at 4:00 p.m. Eastern Time at the St. Regis in New York.

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, a FDA-approved antibacterial drug for the treatment of adult patients with *Clostridium difficile*-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

SOURCE Optimer Pharmaceuticals, Inc.

News Provided by Acquire Media